Development of new agents that regulate cellular signal transduction
Development of new agents that regulate cellular signal transduction
批准号:
15208012
负责人:
OHIGASHI Hajime
金额:
$28.45万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (A)
财政年份:
2003
资助国家:
日本
项目状态:
已结题
起止时间:
2003 至 2006
中文摘要
蛋白激酶C (PKC)同工酶是促肿瘤磷酸酯的主要受体。它们含有两个富含半胱氨酸的C1结构域(C1A, C1B),这两个结构域都是phorbol 12,13-二丁酸酯(PDBu)结合位点的候选结构域。为了从分子水平研究促肿瘤机制,我们合成了所有PKC同工酶C1结构域对应的C1肽,并测定了它们对PDBu的解离常数。利用得到的C1肽文库筛选具有PKC同工酶和C1结构域选择性的新配体,发现吲哚内酰胺- v (IL-V)是一个很有前景的先导化合物。我们利用IL-V的突变肽证实了IL-V的吲哚环可能参与PKCδ C1B结构域Pro-11与CH/π的相互作用,其中Pro-11第4位的氢原子被氟原子取代抑制了CH/π的相互作用。与野生型肽相比,IL-V与突变肽的结合亲和力降低了约10倍,这表明CH/π相互作用中的More可能在IL-V与PKCδ C1B结构域的结合中起关键作用。另一方面,用苯环代替IL-V的吲哚环的苯内酰胺- v8 (BL-V8)可能缺乏CH/π相互作用。通过合成萘内酰胺- v8,可以有效地形成CH/n相互作用,从而增强BL-V8的低结合亲和力。基于PKC同工酶CH/π相互作用的差异,开发了对PKC同工酶(δ,ε,η,θ)具有较强选择性的1-己基吲哚内酰胺- v10和8-辛基苯内酰胺- v9。此外,设计合成了一种疏水性较低的促肿瘤应用毒素的简化类似物,并显示其能将PKCδ从细胞质转移到核膜上,与苔藓抑素1一样具有抗肿瘤活性。近年来,除PKC外,又有新的磷酯受体(n-chimaerins, Unc-13s, RasGRPs)被报道。我们通过合成所有DGK同工酶的C1肽,明确地证明了二酰基甘油激酶(DGK) γ和β是促肿瘤磷酸酯的新靶点。少
英文摘要
Protein kinase C (PKC) isozymes are major receptors of tumor-promoting phorbol esters. They contain two cysteine-rich C1 domains (C1A, C1B), both of which are candidates for phorbol 12,13-dibutyrate (PDBu) binding sites. To investigate the mechanism of tumor promotion in molecular level, the C1 peptides corresponding to the C1 domains of all PKC isozymes were synthesized, and their dissociation constants for PDBu were measured. The resultant C1 peptide library was used to screen for new ligands with PKC isozyme and C1 domain selectivity to find that indolactam-V (IL-V) is a promising lead compound.We verified that the indole ring of IL-V could be involved in the CH/πinteraction with Pro-11 of the C1B domain of PKCδ using its mutant peptide, in which the CH/π interaction was inhibited by substitution of the hydrogen atom with a fluorine atom at position 4 of Pro-11. IL-V showed about a 10 times lower binding affinity to the mutant peptide compared to the wild-type peptide, suggesting th … More at the CH/π interaction could play a pivotal role on the binding of IL-V to the PKCδ C1B domain. On the other hand, benzolactam-V8 (BL-V8), with the benzene ring instead of the indole ring of IL-V, might lack the CH/π interaction. The low binding affinity of BL-V8 could be enhanced by the effective formation of the CH/n interaction as exemplified by the synthesis of naphtholactam-V8. Based on the difference among the CH/π interaction in PKC isozymes, 1-hexyl-indolactma-V10 and 8-octyl-benzolactam-V9 with potent selectivity for novel PKC isozymes (δ,ε,η,θ) that play significant roles in tumor promotion were developed. Moreover, a simplified analogue of tumor-promoting aplysiatoxin with less hydrophobicity was design-synthesized and shown to translocate PKCδ from cytosol to nuclear membrane like bryostatin 1 with anti-neoplastic activity.Recently, new phorbol ester receptors other than PKC (n-chimaerins, Unc-13s, and RasGRPs) have been reported. We unambiguously demonstrated that diacylglycerol kinase (DGK) γ and β are new targets of tumor-promoting phorbol esters by synthesizing the C1 peptides of all DGK isozymes. Less
期刊论文(62)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Development of new medicinal leads based on the CH/π interaction.
基于 CH/π 相互作用开发新的药物先导化合物。
DOI:
--
发表时间:
2006
期刊:
Pharmacia 42 (5)
影响因子:
--
作者:
[Hiradate, S., (Hiradate, S.), K.Irie]
通讯作者:
K.Irie
ペプチド合成によるホルボールエステル受容体の機能解析
肽合成佛波酯受体的功能分析
DOI:
--
发表时间:
2004
期刊:
化学と生物 42・1
影响因子:
--
作者:
[Oguchi, R., K.Hikosaka, T.Hiura, T.Hirose, 入江 一浩]
通讯作者:
入江 一浩
Design and synthesis of 8-octyl-benzolactam-V9, the selective activator for PKCε and η
PKCε 和 η 选择性激活剂 8-辛基-苯并内酰胺-V9 的设计与合成
DOI:
--
发表时间:
2006
期刊:
Journal of Medicinal Chemistry 49・9
影响因子:
--
作者:
[Miyake, H., Yu Nakagawa]
通讯作者:
Yu Nakagawa
Tumor promoter binding of the protein kinse C C1 homology domain peptides of RasGRPs, chimaerins, and Unc13s
RasGRP、嵌合蛋白和 Unc13 的蛋白激酶 C C1 同源结构域肽的肿瘤启动子结合
DOI:
--
发表时间:
2004
期刊:
Bioorganic & Medicinal Chemistry 12・7
影响因子:
--
作者:
[比嘉祐子, 小野裕, 北原曜, Kazuhiro Irie]
通讯作者:
Kazuhiro Irie
CH/π 相互作用を利用した薬剤開発
利用 CH/π 相互作用进行药物开发
DOI:
--
发表时间:
2006
期刊:
ファルマシア 42・5
影响因子:
--
作者:
[Ohtsu, K, 入江 一浩]
通讯作者:
入江 一浩
共 20 条
Rational design of mixing ratio of food-derived anti-inflammatory factors based on molecular mechanisms.
-
批准号:23658119
-
项目类别:Grant-in-Aid for Challenging Exploratory Research
-
资助金额:$1.5万
-
财政年份:2011
-
负责人:OHIGASHI Hajime
-
依托单位:
Exploration of anti-inflammatory food factors from plant diets, and chemical classification of such factors based on their action mechanisms
-
批准号:20580139
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.0万
-
财政年份:2008
-
负责人:OHIGASHI Hajime
-
依托单位:
Prevention of colon cancer with the de novo suppressants of iNOS and COX-2 expressions
-
批准号:12556018
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$7.68万
-
财政年份:2000
-
负责人:OHIGASHI Hajime
-
依托单位:
Ecochemical study on the medicinal plant use of primates in the wild
-
批准号:08306005
-
项目类别:Grant-in-Aid for Scientific Research (A)
-
资助金额:$9.79万
-
财政年份:1996
-
负责人:OHIGASHI Hajime
-
依托单位:
Bioactive phytochemicals from African savanna woodland
-
批准号:07041139
-
项目类别:Grant-in-Aid for international Scientific Research
-
资助金额:$2.62万
-
财政年份:1995
-
负责人:OHIGASHI Hajime
-
依托单位:
Plants medicinally used by chimpnazees in the wild, and their biologically active constituents
-
批准号:06303012
-
项目类别:Grant-in-Aid for Co-operative Research (A)
-
资助金额:$8.38万
-
财政年份:1994
-
负责人:OHIGASHI Hajime
-
依托单位:
Evaluation of dietary plants for superoxide generation (or its inhibition), or scavening activities, and their active constituents
-
批准号:06660156
-
项目类别:Grant-in-Aid for General Scientific Research (C)
-
资助金额:$1.28万
-
财政年份:1994
-
负责人:OHIGASHI Hajime
-
依托单位:
Antiparasitic Agents from Wild Primate Medicinal Plants
-
批准号:06044122
-
项目类别:Grant-in-Aid for international Scientific Research
-
资助金额:$2.05万
-
财政年份:1994
-
负责人:OHIGASHI Hajime
-
依托单位:
Plants non-nutritiously ingested by wild chimpanzee, and their bioactive constituents
-
批准号:04660143
-
项目类别:Grant-in-Aid for General Scientific Research (C)
-
资助金额:$1.28万
-
财政年份:1992
-
负责人:OHIGASHI Hajime
-
依托单位:
国内基金
海外基金
Bryostatin逆转耗竭型CD8+T细胞表观遗传修饰在恶性胸腔积液中的治疗作用及其机制研究
-
批准号:82300121
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:赵满芝
-
依托单位:
天然产物Bryostatin5的克级规模的全合成
-
批准号:CSTB2023NSCQ-MSX0240
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2023
-
负责人:徐标
-
依托单位: